<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/98AD2900-1A5E-4BCC-8C41-F1BE4359A686"><gtr:id>98AD2900-1A5E-4BCC-8C41-F1BE4359A686</gtr:id><gtr:firstName>Moira</gtr:firstName><gtr:surname>Cheung</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800359"><gtr:id>B9B6104A-F58A-4E75-8833-6F950A81AE79</gtr:id><gtr:title>Crosstalk between thyroid hormone and Wnt signalling in osteoblasts</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800359</gtr:grantReference><gtr:abstractText>Thyroid hormone (T3) excess causes bone loss, although the underlying mechanisms are unknown. A key cell signalling route in bone is the ?Wnt? pathway. Suppression of Wnt results in high bone turnover leading to bone fragility and osteoporosis, a situation that also occurs in response to T3-excess. Conversely, increased Wnt signalling causes increased bone mass, resembling effects of T3-deficiency on the skeleton. Interactions between T3 and Wnt are well known in intestine, pituitary and kidney but have never been studied in bone. Preliminary studies have shown that Wnt signalling is decreased in bone forming cells (osteoblasts) in response to T3. Dr. Moira Cheung and Professor Graham Williams of the MRC Clinical Sciences Centre, Imperial College London, will study how thyroid hormones inhibit Wnt signalling to regulate osteoblast activity.

They will determine:
o Which components of the Wnt pathway are regulated by T3
o Interactions between T3 and the Wnt pathway in osteoblasts
o Whether T3 receptors interact with important components of the Wnt pathway

Understanding the mechanisms by which T3 acts on bone is important because it may lead to new treatments for osteoporosis, a condition that causes over 230,000 fractures each year costing the NHS over &amp;pound;1.7 billion.</gtr:abstractText><gtr:technicalSummary>Aims: Excess thyroid hormone (T3) accelerates bone loss causing osteoporosis. Canonical Wnt signalling in osteoblasts regulates bone turnover via a pathway that results in the binding of -catenin to the Tcf/Lef transcription factor. Inhibition of Wnt results in a high turnover, low bone mass phenotype similar to that seen in thyrotoxicosis, whereas increased -catenin activity leads to high bone mass analogous to findings in hypothyroidism. Recent evidence has revealed interaction between T3 and Wnt signalling in various tissues but no studies have been performed in bone. Our preliminary data reveal down-regulation of Wnt signalling in osteoblasts from mice with skeletal thyrotoxicosis and osteoporosis. I hypothesise that T3 regulates osteoblast activity by inhibition of canonical Wnt signalling. 

Objectives: I will determine:
1. Which components of the Wnt pathway are regulated by T3 in osteoblasts 
2. Interactions between T3 and Wnt in osteoblasts
3. Whether T3 receptors interact with active members of the Wnt pathway in osteoblasts

Design and Methodology: 
1. Analysis of gene expression in primary osteoblasts from WT, TR 0/0, TR -/- and TR 0/0 -/- knockout mice following treatment with T3 or vehicle by microarray. Differential expression of key genes will be verified independently by RT-qPCR and in immunohistochemistry studies using tissue from mutant mice.
2. Interactions between T3 and Wnt will be studied in WT, TR 0/0 and TR -/- osteoblasts by analysis of effects on cell differentiation, accumulation of -catenin and expression of Wnt and T3 target genes. 
3. Co-localisation of T3 receptors, -catenin and Tcf/Lef will be examined using immunofluorescence confocal microscopy and physical interactions will be studied in co-immunoprecipitation, GST pull-down and gel mobility shift assays.

Scientific Opportunities: Thyroid hormones are essential for accrual of peak bone mass during growth and regulate bone turnover in adults. The canonical Wnt pathway has a major role in the control of bone formation and mineralisation. Strong evidence indicates that T3 interacts with the Wnt pathway in a variety of tissues. Bone has not been investigated, but our preliminary data suggests that T3 inhibits the Wnt pathway in osteoblasts. By characterising interactions between T3 and Wnt in osteoblasts we will determine molecular mechanisms by which thyroid and Wnt signalling converge to regulate osteoblast differentiation and activity.

Medical Opportunities: Osteoporosis affects a third of women and one in eight men, and over 230,000 fractures each year cost the NHS &amp;pound;1.7 billion. This research will facilitate identification of new anabolic drug targets for the treatment of osteoporosis.</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-01-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>289606</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>63AE21FC-D5FB-4FA5-BDDD-54C0137EA0F1</gtr:id><gtr:title>Mice lacking the calcineurin inhibitor Rcan2 have an isolated defect of osteoblast function.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99d7464b25b98fd943ea2dd96c9c6424"><gtr:id>99d7464b25b98fd943ea2dd96c9c6424</gtr:id><gtr:otherNames>Bassett JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>pm_16261_21_22593270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16A287A6-9B8B-4E14-9565-E58CA96D6735</gtr:id><gtr:title>Genetic evidence that thyroid hormone is indispensable for prepubertal insulin-like growth factor-I expression and bone acquisition in mice.</gtr:title><gtr:parentPublicationTitle>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c732ef826ba5ff7ab85ec40efc25b8f3"><gtr:id>c732ef826ba5ff7ab85ec40efc25b8f3</gtr:id><gtr:otherNames>Xing W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0884-0431</gtr:issn><gtr:outcomeId>585d5ab3961117.55483711</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800359</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>